Isturisa® (osilodrostat) – Expanded indication
April 16, 2025 - Recordati announced the FDA approval of Isturisa (osilodrostat), for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative.
Download PDF
